Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

The study has five core arms and the stratification is based on site and age. In addition,
there are 4 possible contingent groups of which 2 will be studied based on an analysis
concerning immunogenicity performance at Day 42 in core groups above.

Inclusion Criteria:

- Male and female adults 18 to 64 years of age at time of first vaccination, inclusive.

- Good general health as assessed by medical history and physical examination.

- Access to a consistent means of telephone contact

- Written informed consent obtained from the subject.

- Comprehension of the study requirements, expressed availability for the required study
period, and ability to attend scheduled visits.

- Subjects who the investigator believes that they can and will comply with the
requirements of the protocol should be enrolled in the study.

Exclusion Criteria:

- Presence of significant acute or chronic, uncontrolled medical or psychiatric illness

- Presence of evidence of substance abuse or of neurological or psychiatric diagnoses
which, although stable, are deemed by the investigator to render the potential subject
unable/unlikely to provide accurate safety reports.

- Blood pressure abnormalities

- Diagnosed with cancer, or treatment for cancer, within 3 years.

- Persons with a history of cancer who are disease-free without treatment for 3 years or
more are eligible.

- Persons with a history of histologically-confirmed basal cell carcinoma of the skin
successfully treated with local excision only are excepted and may enroll, but other
histologic types of skin cancer are exclusionary.

- Women who are disease-free 3 years or more after treatment for breast cancer and
receiving long-term prophylactic tamoxifen are excepted and may enroll.

- Presence of an oral temperature ≥ 37.8º C, or acute symptoms greater than "mild"
severity on the scheduled date of first vaccination.

- Any confirmed or suspected immunosuppressive or immunodeficient condition including
history of human immunodeficiency virus (HIV) infection.

- Receipt of cytotoxic or immunosuppressive drug within 6 months of study enrollment.

- Any significant disorder of coagulation or treatment with Coumadin derivatives or
heparin.

- Administration of any non-influenza vaccines within 30 days before study enrollment or
during the study period.

- Use of any investigational or non-registered product (drug or vaccine) or planned
participation in another investigational study within 30 days prior to study
enrollment, or during the study period.

- Receipt of any immunoglobulins and/or any blood products within 3 months of study
enrollment or planned administration of any of these products during the study period.

- Any known or suspected allergy to any constituent of influenza vaccines.

- Known pregnancy or a positive urine beta-human chorionic gonadotropin (ß-hCG) test
result prior to dosing on Study Days 0 or 21.

- Lactating or nursing.

- Women of child bearing potential who lack a history of reliable contraceptive
practices.

- Known receipt of analgesic or antipyretic medication on the day of treatment